Loading organizations...
Loading organizations...
Developing SLC transporter inhibitors for cancer treatment.
Atransen Pharma has raised $9.4M across 1 funding round.
Atransen Pharma has raised $9.4M in total across 1 funding round.
Atransen Pharma has raised $9.4M in total across 1 funding round.
Atransen Pharma's investors include Angel Bridge.
Atransen Pharma has raised $9.4M across 1 funding round. Most recently, it raised $9.4M Series A in December 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 23, 2025 | $9.4M Series A | Angel Bridge |